We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Agennix announced that the FDA has granted fast-track designation to the company's Talactoferrin Alfa (TLF) clinical development programs for first-line non-small-cell lung cancer and diabetic foot ulcers.
Positive Phase III data presented at the European Academy of Dermatology and Venereology Congress showed that Abbott's Humira was statistically superior to methotrexate in patients with psoriasis.
SkyePharma has announced positive results of a Phase III clinical trial of Lodotra, a new, modified-release tablet that has been developed in partnership with Nitec Pharma to optimize the efficacy of orally administered low-dose prednisone in rheumatoid arthritis (RA).
Isotechnika has announced final safety and efficacy data after 60 weeks of continuous treatment with ISA247 for psoriasis. All safety and efficacy endpoints were met.
Biogen Idec Canada and Elan have announced that, following a priority review process, Health Canada has granted approval to Tysabri (natalizumab) for the treatment of relapsing-remitting multiple sclerosis (MS).
Epeius Biotechnologies announced it has received a R01 grant from the FDA to assist in the evaluation of a Phase I/II clinical trial using Rexin-G for advanced or metastatic pancreatic cancer.